Fusion Antibodies (LSE:FAB) has reported a narrower loss and a stronger balance sheet for the year to 31 March 2026, but its board has also flagged that difficult market conditions are weighing on the first half of the new financial year. The Belfast-based antibody specialist published its final results on 14 September 2026, showing modest revenue growth, a sharp improvement in gross margin and a strategic push towards a technology licensing model, alongside a going concern material uncertainty that investors are likely to watch closely.

What the Company Does

Fusion Antibodies is a contract research organisation focused on antibody engineering. It provides services such as antibody humanisation, sequencing and stable cell line development to pharmaceutical and biotechnology clients, many of them in North America. In recent years it has been building proprietary technology, most notably its OptiMAL platform, a library-based approach to antibody discovery that the company launched commercially in December 2025. Management has said it intends to shift the business towards licensing its technology to generate more recurring revenue, rather than relying solely on project-based service work.

Latest Developments

In its final results, the company reported revenue of £2.11m for the 2026 financial year, up about 7% from £1.97m a year earlier. That figure included a one-off £250k sale of intellectual property to Finn Therapeutics; underlying service revenue actually fell about 5% to £1.86m.

Operationally, chief executive Adrian Kinkaid described the year as another of important progress. Validation work with the US National Cancer Institute continued, and the company said a formal screening agreement with the NCI is under negotiation, though the timing remains uncertain. After the year end, patents covering the Opti library were granted in Japan, allowed in Canada and accepted in Australia. The company is also targeting a pre-clinical DR5 asset, developed with Queen's University Belfast, for partnering from late in the 2027 financial year.

Financial Picture

Gross margin rose to 53% from 22% the year before, helped by the IP sale and better underlying margins. Other operating income of £872k, largely from a Future Medicines Institute grant, supported the result. The operating loss narrowed to £1.13m from a restated £1.63m, even with research and development spending of £861k, and the loss for the year was £1.15m, or 1.2p per share.

Cash stood at £1.04m at the year end, up from £0.36m, after a placing in January 2026 that raised about £1.3m net at 13p per share. However, the directors reported a material uncertainty over going concern, saying additional funding is expected to be needed within the assessment period. No dividend was reported.

Sector and Index Context

As a micro-cap constituent of the FTSE AIM All Share Index, Fusion sits in a corner of the market where funding conditions for small biotech customers directly affect demand for outsourced services. The company has said it is diversifying towards larger pharmaceutical clients to improve visibility and reduce exposure to the funding cycles of smaller biotechs.

Key Risks

The most immediate risk is financing: the going concern statement makes clear that further capital is likely to be required, which could dilute existing shareholders. Revenue is lumpy and project-driven, and chairman Simon Douglas cautioned that growth may be slow, with first-half performance in the 2027 financial year adversely affected by market conditions. Collection of the Finn receivable and the timing of any NCI agreement are further uncertainties.

What to Watch Next

Investors will be looking for the half-year trading picture, progress on a formal NCI agreement, any first licensing deals for OptiMAL, and news on funding. Receipt of the Finn Therapeutics payment, which was fully provided for, would also be notable.